FOXA1 and liver cancer: Finally, combining FOXA1 silencing or miRNA-212-3p mimic with doxorubicin resulted in a fourfold increase in apoptosis induction in HepG2/Dox cells, suggesting that targeting FOXA1 can effectively restore drug sensitivity in resistant liver cancer cells.